Ramsay Health (ASX:RHC) share price presents a reopening play: Fund manager

Could Ramsay Health make for a reopening investment? This fundie believes so…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Ramsay Health Care Limited (ASX: RHC) share price has been an underperformer over the past year. During the last 12 months, shares in the healthcare facility operator have traded sideways, gaining ~2%. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) has dished out a 23.7% return to investors over the same period.

Although, one fund manager is betting on the tide turning as COVID-19 restrictions ease across its operating geographies.

Let's take a look at why Sydney-based Perennial Partners are bullish on the Ramsay Health share price.

A woman opens and reaches into a big cardboard box, with a big smile on her face.

Image source: Getty Images

A big backlog filtering through

Firstly, the Perennial Value Australian Shares Trust invests in a broad swathe of ASX shares, with the aim of outperforming the S&P/ASX 300 Accumulation Index on a rolling 3-year basis. At the end of August, the trust held $761 million in funds under management.

To outperform the index, the fund must attempt to balance its investment weightings better than the index itself. As such, compared to the index, the Perennial Value fund is underweight on Rio Tinto Limited (ASX: RIO), Transurban Group (ASX: TCL), Goodman Group (ASX: GMG), Australia and New Zealand Banking Group Ltd (ASX: ANZ), and Afterpay Ltd (ASX: APT).

On the contrary, there are several ASX-listed companies in which the fund sees greater upside potential. One of these shares is Ramsay Health Care. As a result, the Perennial Value fund is overweight with Ramsay when comparing to its benchmark index.

In the near term, elective surgery restrictions in Australia are impacting the healthcare company's earnings. However, looking beyond this, the fund points out a likely bounce back in surgical volumes once restrictions lift.

Providing justification, Perennial drew attention to the increase in volumes in Ramsay's United Kingdom operations. Considering the UK is largely open again, procedures deferred by COVID-19 are now being tended to.

According to the Australian Institute of Health and Welfare, the median waiting time for elective surgery in Australia for 2019-2020 increased to 77 days from 66 days. On a similar note, The Age recently reported a significant blowout in Victoria's hospital waiting lists.

Specifically, the state's elective surgery waiting list has reached more than 65,000 people – with more than 30,000 procedures being cancelled last year.

Positioning for upside in Ramsay Health share price

The Perennial fund is putting its (investors') money where its mouth is. According to the trust's activity in August, the fund took profits in some of its outperforming holdings and redirected that capital elsewhere.

In gearing up for a reopening boom, Perennial allocated those proceeds to several ASX shares, including Ramsay Health.

The Ramsay Health share price finished the Monday trading session at $69.28.

Motley Fool contributor Mitchell Lawler owns shares of AFTERPAY T FPO and Ramsay Health Care Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia owns shares of and has recommended AFTERPAY T FPO. The Motley Fool Australia has recommended Ramsay Health Care Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A elder man and woman lean over their balcony with a cuppa, indicating share rpice movement for ASX retirement shares
Healthcare Shares

Regis Healthcare expects FY26 EBITDA to hit top end of guidance

Regis Healthcare expects top-end FY26 earnings as strong occupancy, RAD inflows, and efficiency gains set a positive outlook.

Read more »

A man holding a cup of coffee puts his thumb up and smiles with a laptop open.
Healthcare Shares

This ASX healthcare stock could be set to rise 50%

This small cap could be one to watch.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

Up 60%: Why this exciting ASX stock could keep rising

This speculative stock could still have significant upside according to Bell Potter.

Read more »

A person holds their hands up through the middle of a rubber lifesaving ring while swimming in relatively calm conditions at a beach.
Healthcare Shares

Why this ASX healthcare high-flyer just dropped another 9% today

4DMedical shares are sliding again. Here’s what’s behind the drop.

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

Mayne Pharma stock jumps 8% on strong Q3 update. Has it finally bottomed?

Mayne Pharma's share price has rebounded 32% since hitting a five-year low in March.

Read more »

A young woman sits with her hand to her chin staring off to the side thinking about her investments.
Healthcare Shares

Down 65%, are Cochlear shares a once-in-a-decade buying opportunity?

After a brutal drop, sentiment has turned negative. But looking beyond the next year, the long-term story may still be…

Read more »

Two lab workers fist pump each other.
Healthcare Shares

A big milestone for this ASX biotech. Here's why the share price is moving

Mesoblast hits a key trial milestone...

Read more »

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Healthcare Shares

Mesoblast shares in focus after key Phase 3 milestone for low back pain

Mesoblast shares are in focus after reaching a major patient recruitment milestone in its pivotal Phase 3 trial for chronic…

Read more »